Keyword: Shire

In a move to bolster its access to plasma, Shire snapped up Swiss source plasma collection company Sanaplasma for an undisclosed price.

BioCryst says its BCX7353 drug effectively treated acute hereditary angioedema attacks in a midstage trial, setting up a possible registration study.

Shire has quietly cut the trial of an FDA fast-tracked fatty liver disease drug, although it’s not giving much away about what happened.

Enyo Pharma raised nearly $47 million to launch the first two phase 2 clinical trials of EYP001, its lead candidate in hep B and NASH, before 2019.

The IPO will tee Translate up to trial an mRNA candidate designed to enable all cystic fibrosis patients to produce fully functional CTFR proteins.

Using an old Roche drug, Madrigal Pharmaceuticals has seen its stock soar 130% on its latest fatty liver disease trials data.

The IPO would give Avrobio the means to trial gene therapies designed to supplant enzyme replacement therapies from Sanofi, Shire and Pfizer.

Takeda's $62 billion acquisition of Shire added $31 billion to its debt load. Now, it's looking to cut costs where it can.

Takeda's plan involves signing on one or more large, long-term investors, as well as keeping its R&D pipeline alive by discarding programs that don't deliver.

Kamada has hit another hurdle in its bid to bring the first inhaled treatment for AAT deficiency to market as an alternative to intravenous drugs.